News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
883,773 Results
Type
Article (88774)
Company Profile (816)
Press Release (794160)
Multimedia
Podcasts (238)
Webinars (35)
Section
Business (233589)
Career Advice (4162)
Deals (39988)
Drug Delivery (177)
Drug Development (91701)
Employer Resources (207)
FDA (18553)
Job Trends (17486)
News (398727)
Policy (40013)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (4)
2027 Genetown Standard (5)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (6)
Academia (3053)
Academic (2)
Accelerated approval (56)
ADA (49)
Adcomms (40)
Allergies (196)
Alliances (56990)
ALS (236)
Alzheimer's disease (1967)
Antibody-drug conjugate (ADC) (551)
Approvals (18892)
Artificial intelligence (867)
ASCO (345)
Autoimmune disease (361)
Automation (64)
Bankruptcy (407)
Best Places to Work (12635)
BIOSECURE Act (23)
Biosimilars (248)
Biotechnology (480)
Bladder cancer (211)
Brain cancer (85)
Breast cancer (837)
Cancer (6566)
Cardiovascular disease (554)
Career advice (3597)
Career pathing (52)
CAR-T (384)
CDC (76)
Celiac Disease (3)
Cell therapy (1069)
Cervical cancer (54)
Clinical research (78989)
Collaboration (2365)
Company closure (8)
Compensation (1508)
Complete response letters (106)
COVID-19 (3041)
CRISPR (124)
C-suite (1282)
Cystic fibrosis (167)
Data (8673)
Decentralized trials (3)
Denatured (91)
Depression (193)
Dermatology (96)
Diabetes (703)
Diagnostics (7595)
Digital health (69)
Diversity (14)
Diversity, equity & inclusion (49)
Drug discovery (424)
Drug pricing (245)
Drug shortages (39)
Duchenne muscular dystrophy (318)
Earnings (102482)
Editorial (78)
Employer branding (25)
Employer resources (174)
Events (138640)
Executive appointments (1192)
FDA (22615)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (19)
Frontotemporal dementia (36)
Funding (1939)
Gene editing (270)
Generative AI (89)
Gene therapy (849)
GLP-1 (1284)
Government (5559)
Grass and pollen (8)
Guidances (419)
Healthcare (21259)
Hematology (198)
HIV (94)
Huntington's disease (64)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (115)
Immunology and inflammation (352)
Immuno-oncology (116)
Indications (206)
Infectious disease (3439)
Inflammatory bowel disease (242)
Inflation Reduction Act (17)
Influenza (148)
Intellectual property (322)
Interviews (821)
IPO (18001)
IRA (61)
Job creations (5209)
Job search strategy (2871)
JPM (73)
Kidney cancer (23)
Labor market (122)
Layoffs (686)
Leadership (53)
Legal (10171)
Liver cancer (111)
Longevity (37)
Lung cancer (873)
Lymphoma (465)
Machine learning (66)
Management (66)
Manufacturing (1220)
MASH (226)
Medical device (15276)
Medtech (15434)
Mergers & acquisitions (23285)
Metabolic disorders (1820)
mRNA (266)
Multiple sclerosis (204)
NASH (24)
Neurodegenerative disease (507)
Neuropsychiatric disorders (126)
Neuroscience (3712)
Neurotech (2)
NextGen: Class of 2026 (7715)
Non-profit (5145)
Now hiring (80)
Obesity (869)
Opinion (374)
Ovarian cancer (244)
Pain (284)
Pancreatic cancer (350)
Parkinson's disease (417)
Partnered (39)
Patents (654)
Patient recruitment (757)
Peanut (70)
People (67991)
Pharmaceutical (136)
Pharmacy benefit managers (37)
Phase 1 (24413)
Phase 2 (34306)
Phase 3 (25802)
Pipeline (9729)
Policy (397)
Postmarket research (3559)
Preclinical (10978)
Press Release (72)
Prostate cancer (347)
Psychedelics (68)
Radiopharmaceuticals (373)
Rare diseases (1261)
Real estate (7462)
Recruiting (81)
Regulatory (30379)
Reports (77)
Research institute (2771)
Resumes & cover letters (654)
Rett syndrome (42)
RNA editing (29)
RSV (98)
Schizophrenia (196)
Series A (327)
Series B (237)
Service/supplier (28)
Sickle cell disease (127)
Special edition (32)
Spinal muscular atrophy (190)
Sponsored (55)
Startups (4371)
State (2)
Stomach cancer (21)
Supply chain (146)
Tariffs (104)
The Weekly (144)
Vaccines (1306)
Venture capital (133)
Weight loss (597)
Women's health (141)
Worklife (24)
Date
Today (133)
Last 7 days (675)
Last 30 days (3306)
Last 365 days (33276)
2026 (16136)
2025 (33218)
2024 (38123)
2023 (42564)
2022 (53928)
2021 (58720)
2020 (57663)
2019 (51334)
2018 (39119)
2017 (37188)
2016 (38329)
2015 (44432)
2014 (39672)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1296)
Alabama (102)
Alaska (7)
Arizona (402)
Arkansas (16)
Asia (52291)
Australia (9192)
California (14361)
Canada (4010)
China (1570)
Colorado (618)
Connecticut (639)
Delaware (443)
Europe (120590)
Florida (2130)
Georgia (467)
Hawaii (4)
Idaho (70)
Illinois (1250)
India (102)
Indiana (663)
Iowa (25)
Japan (591)
Kansas (143)
Kentucky (56)
Louisiana (64)
Maine (89)
Maryland (1740)
Massachusetts (10507)
Michigan (422)
Minnesota (799)
Mississippi (7)
Missouri (164)
Montana (37)
Nebraska (30)
Nevada (153)
New Hampshire (92)
New Jersey (3808)
New Mexico (35)
New York (3776)
North Carolina (1937)
North Dakota (11)
Northern California (7140)
Ohio (449)
Oklahoma (27)
Oregon (55)
Pennsylvania (2829)
Puerto Rico (30)
Rhode Island (54)
South America (1668)
South Carolina (88)
South Dakota (2)
Southern California (5632)
Tennessee (227)
Texas (2339)
United States (51383)
Utah (426)
Vermont (1)
Virginia (363)
Washington D.C. (89)
Washington State (1179)
West Virginia (4)
Wisconsin (160)
Wyoming (2)
There are 883,773 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Events
11th CAR-TCR Summit
Advancing the Development of Targeted, Scalable Cell Therapies through Disruptive Ex Vivo & In Vivo Technologies, Automated Manufacturing & Strategic Partnerships to Safeguard the Commercial Success of the Industry
June 11, 2026
Press Releases
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
June 11, 2026
·
11 min read
Press Releases
Xeris Biopharma Announces Private Exchange of Convertible Notes
June 11, 2026
·
4 min read
Press Releases
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
June 11, 2026
·
15 min read
IPO tracker
Kardigan stitches up $369M IPO plan
Analysts are cautiously optimistic about an IPO rebound for biopharma.
BioSpace
is keeping track of companies that seek to trade on the public markets this year.
June 11, 2026
·
16 min read
·
Editorial Team
Press Releases
ZEISS announces successful early implantations of the AT LUCIA toric 721P intraocular lens
June 11, 2026
·
5 min read
Press Releases
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
June 11, 2026
·
5 min read
Press Releases
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
June 11, 2026
·
7 min read
Press Releases
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
June 11, 2026
·
15 min read
Press Releases
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
June 11, 2026
·
8 min read
1 of 88,378
Next
